𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rivastigmine for alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications

✍ Scribed by Jean-François Baladi; Peter A.B. Bailey; Sandra Black; Rémi W. Bouchard; Karl D. Farcnik; Serge Gauthier; Andrew Kertesz; Erich Mohr; Alain Robillard

Book ID
117320930
Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
957 KB
Volume
22
Category
Article
ISSN
0149-2918

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Assessing the cost-effectiveness of the
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models
✍ Balázs Nagy; Alan Brennan; Ágnes Brandtmüller; Simu K. Thomas; Sean D. Sullivan; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

Assess long-term cost-effectiveness of rivastigmine patch in Alzheimer's disease (AD) management in the UK, using cognitive and functional models based on clinical trial efficacy data. Methods: Incremental costs and Quality Adjusted Life Years (QALYs) associated with rivastigmine patch and capsule t

Review of donepezil, rivastigmine, galan
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population
✍ V. P. Prasher 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 74 KB 👁 2 views

## Abstract The management of dementia in Alzheimer's disease has dramatically changed since the development of anti‐dementia drugs. However, there is limited information available regarding the bio‐medical aspects of the differing drugs; particularly relating to adults with intellectual disability